マサチューセッツ州における子宮頸がんの臨床試験
マサチューセッツ州内の拠点で、子宮頸がんに関する19件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07227168A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT
- Massachusetts General Brigham, Boston
被験者募集中
21歳〜70歳 · 女性 · 2026/08/07更新 · NCT06872346First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- 他3件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06239194Building Connections
- Disparities Research Unit, Massachusetts General Hospital, Boston
被験者募集中
18歳〜75歳 · 全性別 · 2025/11/18更新 · NCT07091032Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 女性 · 2025/11/05更新 · NCT06677190SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/24更新 · NCT05941507ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。